- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02778113
A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults
A Single Site, Randomized, Four-Way, Four-Period PK/PD Crossover Phase 1 Clinical Study in 16 Fasted Healthy Adult Volunteers Receiving 3 Dose Levels of Intranasally Administered Glucagon and One Dose Level of Glucagon Administered by Subcutaneous Injection
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Quebec
-
Mount-Royal, Quebec, Canada, H3P 3P1
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Body mass index (BMI) greater than or equal to 20.00 and below or equal to 28.00 kg/m².
- Light-, non- or ex-smokers.
- Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis).
Exclusion Criteria:
- Presence of any nose piercings.
- History of significant hypersensitivity to glucagon or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
- Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.
- Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease.
- Presence of clinically significant findings on nasal examination and bilateral anterior rhinoscopy.
- Fasting blood glucose above 5.0 millimoles per liter (mmol/L) at screening, following a 12-hour fasting period.
- Fasting blood glucose assessed with a glucose meter above 5.5 mmol/L 0.5 hour before each dosing.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Nasal Glucagon (NG) - 0.5 mg
Ng dose at 0.5 milligram (mg) administered once in one of four study periods.
|
Administré par voie intranasale.
Autres noms:
|
Expérimental: NG - 1.0 mg
Ng dose at 1.0 milligram (mg) administered once in one of four study periods.
|
Administré par voie intranasale.
Autres noms:
|
Expérimental: NG - 2.0 mg
Ng dose at 2.0 milligram (mg) administered once in one of four study periods.
|
Administré par voie intranasale.
Autres noms:
|
Comparateur actif: SC Glucagon 1 mg
Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.
|
Administered SC.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Participants With One or More Serious Adverse Event(s) (SAEs)
Délai: Baseline through Study Completion (Day 23)
|
Safety and tolerability evaluated through the assessment of adverse events. A SAE (serious adverse event) was defined as any untoward medical occurrence in a clinical investigation, which did not necessarily have a causal relationship with this treatment. A summary of other non-serious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section. |
Baseline through Study Completion (Day 23)
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon
Délai: Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon
Délai: Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon
Délai: Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon
Délai: Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC₀-₄) of Glucose
Délai: Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose
Délai: Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax)
Délai: Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Day 1: -0.5, -0.25, 0, 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2, 2.5, 3 and 4 hours post dose for each treatment
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 16424
- I8R-MC-IGBD (Autre identifiant: Eli Lilly and Company)
- AMG 101 (Autre identifiant: AMG Medical Inc.)
- GUO-P1-557 (Autre identifiant: AMG Medical Inc.)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur En bonne santé
-
AstraZenecaParexelComplété
Essais cliniques sur Glucagon nasal
-
Eli Lilly and CompanyLocemia Solutions ULCComplété
-
Eli Lilly and CompanyLocemia Solutions ULCComplétéDiabète sucré | Hypoglycémie | Anticorps spécifiques aux médicamentsÉtats-Unis, Canada
-
Eli Lilly and CompanyLocemia Solutions ULCComplétéDiabète sucré | Anticorps spécifiques aux médicamentsCanada
-
Eli Lilly and CompanyComplétéDiabète sucré | HypoglycémieÉtats-Unis
-
Eli Lilly and CompanyComplétéEn bonne santéÉtats-Unis
-
Eli Lilly and CompanyComplétéHypoglycémie | Diabète sucré, type 1Allemagne
-
Eli Lilly and CompanyJaeb Center for Health Research; Locemia Solutions ULCComplétéDiabète sucré, type 1États-Unis
-
Eli Lilly and CompanyLocemia Solutions ULC; T1D Exchange Clinic Network Coordinating CenterComplétéDiabète sucré, type 1États-Unis
-
Eli Lilly and CompanyLocemia Solutions ULCComplétéDiabète sucré, Type 2 | Diabète sucré, type 1Canada
-
Eli Lilly and CompanyLocemia Solutions ULCRésiliéDiabète sucré, Type 2 | Diabète sucré, type 1Canada